For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Selina Chen-Kiang

Professor

Biography

CELL CYCLE CONTROL OF B CELL IMMUNITY and CANCER

We have a long-standing interest in discerning the mechanism of cell cycle control of immunity and translating fundamental discoveries to innovative cancer therapy.  First, we discovered in mice that modulation of the cyclin-dependent kinase 4 (CDK4) and CDK6 activities by a physiologic inhibitor p18INK4c was required for homeostatic cell cycle control of both B cell activation and terminal differentiation to plasma cells in immunity (Immunity. 2002; 17: 179. PMID: 12196289). This led us to demonstrate that dysregulation of CDK4/6 underlies unrestrained proliferation of cancer cells in hematologic malignancies in humans. Recognizing the unexplored therapeutic potential of the first selective CDK4/6 inhibitor (palbociclib), we pioneered a strategy to both inhibit proliferation of cancer cells and reprogram them for therapy vulnerability by inducing prolonged early G1 arrest (pG1) with CDK4/6 inhibition (Cancer Res. 2006; 66:7661. PMID: 16885367). Implementing this novel strategy in multiple hypothesis-driven clinical trials in mantle cell lymphoma (MCL) and multiple myeloma in collaboration with our clinical colleagues indicates that indeed induction of pG1 by CDK4/6 inhibition deepens and prolongs the clinical response to inhibition of BCR signaling (Cancer Discov. 2014;4:1022. PMID: 25082755). By integrated longitudinal functional genomics, we have discovered cancer cell heterogeneity, candidate genomic resistance drivers and novel cancer-immune cell interactions in the context of clinical response to CDK4/6 inhibition in MCL at the single cell resolution. Our current focus is transcriptional and epigenetic reprogramming of cancer cells and cancer- immune cell interaction that discriminate sensitivity from resistance to CDK4/6 inhibition in lymphoma therapy.  To overcome resistance to CDK4/6 inhibition, we have begun to target resistance-dependent vulnerability in MCL. Loss of cell cycle control is a hallmark of human cancer.  Our studies in human lymphoma may have broad mechanistic and clinical implications for targeting the cell cycle in other cancers as well.

Research Topics

Need more info?
Ask a question
Follow us on
Instagram

Weill Cornell Medicine Graduate School of Medical Sciences 1300 York Ave. Box 65 New York, NY 10065 Phone: (212) 746-6565 Fax: (212) 746-5981